Ji Zhicheng City Yantai to build a full -time medical industry chain

Jiaodong Online August 19 (Reporter Wang Xiangrong) Yantai in the late summer and early autumn, the sea breeze is slow, refreshing and pleasant. On the afternoon of August 18th, the Academician and Expert Forum of Medical Homotherapy Drugs and Application Technology was held at the Baying Bay International Conference Center in Yantai City. Many academicians and experts in the field of nuclear medical care gathered to share the global nuclear medicine innovation trend, and seek a new chapter of China Nuclear Medicine Development. , Co -concentration of the development of the nuclear medical industry.

The Academician Expert Forum of Medical Homotherapy Drugs and Application Technology is the highlight of 2022 medical innovation and development of international conferences. The event was hosted by Yantai Dongcheng Pharmaceutical Group Co., Ltd., co -organized by Yantai Muping District Government and Yantai Biomedical Health Industry Development Co., Ltd. The forum invited Deng Jianjun, an academician of the Chinese Academy of Engineering, Deng Jianjun, chief engineer of the Institute of Fluid Physics, Institute of Physics of the Chinese Academy of Engineering, Jiang Jiandong, a member of the Chinese Academy of Engineering, a member of the Chinese Academy of Medical Sciences, and a professor of the dean of Beijing Union Medical Medicine. In his life, Pan Gang, deputy director of the Strategic Consultation Center of the Chinese Academy of Engineering, Huang Gang, president and professor of Shanghai Health Medical College, Yang Zhi, director, professor, and doctoral supervisor of Peking University Cancer Hospital, Yang Zhi, and a doctoral supervisor, and a subject of Beijing Tsinghua Chang Geng Hospital Affiliated to Tsinghua University Director He Zhaoxiang, experts and scholars such as Li Zhongjun, a professor, doctoral supervisor, doctoral supervisor, member of the Party Committee of the Academy, and guests from all walks of life attended the meeting. Professor Huang Gang, Professor Tian Guoxin, researcher at the Chinese Institute of Atomic Energy, Dr. Hu Kuan, a researcher at the Institute of Pharmaceutical Research of Beijing Union Medical College, and Texas A & M University Ph.D. in Zhang Yunhuang delivered a keynote speech.

"Nuclear Medicine is a very important discipline in clinical medicine. It plays an important role in clinical diagnosis, treatment, and research." Professor Huang Gang popularized the connotation and application significance of nuclear medicine. He brought "molecular image and target Speech to the Drug Evaluation, "Nuclear Medicine is an important tool revealed to visualized drugs and drug effects. It can be said that nuclear medicine will make our targeted drugs truly enter the era of precision medicine."

Next, Dr. Zhang Yunhuang explained "Application of Nuclear Medical Applications from Military Workers to Minsheng-Reactor". Academic sharing of several cutting -edge and development trends of drugs.

"There are some key scientific issues in the current development stage in targeted diagnosis and treatment. During the development of nuclear drugs, we are limited by the lack of new targets and the lack of nuclear medicinal molecules. A key scientific issue, looking for the new target and new molecular entities to work hard, spend great energy. "Hu Kuan clarified his views on the development trend of nuclear drugs in targeted diagnosis and nuclear therapy.

At the meeting, Luo Zhigang, general manager of Dongcheng Pharmaceutical, introduced the planning and construction of the Yantai Nuclear Medical Science and Technology Museum, and introduced the content and display methods.

After more than 20 years of development, Dongcheng Pharmaceutical has become a "heparin expert and nuclear pioneer". The company's raw and drug business and nuclear drug business have occupied the important position of the market. Since entering the field of nuclear medicine in 2015, Dongcheng Pharmaceutical's rapid layout has gradually created a complete nuclear pharmaceutical industry chain since scratch, and has become one of the leading companies in China's nuclear pharmaceutical industry. At present, Dongcheng Pharmaceutical has formed a full coverage of "screening -diagnosis -treatment"; 27 sites put into operation in Dongcheng Pharmaceutical Distribution Network, and 30 will be reached. More than %of the population. In the field of diagnosis and treatment services, the company has actively deployed the BNCT business of high -end nuclear medical equipment, and the current progress is smooth. In the field of R & D and innovation, a unique R & D platform led by "Lan Na Cheng" has been formed. It has rich product pipelines, and multiple products with layout have outstanding advantages. At this stage, Dongcheng Pharmaceutical has basically realized the layout of the entire industry chain layout of radioactive drug production, innovative research and development, clinical conversion applications, and research and development and production of nuclear medical treatment equipment to promote the continuous efforts of the industry's development in order to benefit patients and promote the development of the industry.

Luo Zhigang said that as an emerging industry, Nuclear Pharmaceuticals still have problems with imperfect industrial chain. After years of development, the conventional biomedical industry has formed a relatively complete industrial chain. However Nuclear pharmaceutical companies, Dongcheng Pharmaceuticals want to get through the nodes on the production chain. At present, Dongcheng Pharmaceutical is building our production system, improving the entire industrial chain, creating the entire industry chain, and promoting enterprises to take off again. In recent years, Yantai has taken the lead in the field of medical isotopes, and the industrial foundation has been very solid. Yantai City has two oligopoly Dongcheng Pharmaceuticals in the field of medical isotope drugs in my country. The top medical isotopes in the field of medical isotopes, a group of high -level academician experts at home and abroad, and a group of leading enterprises in this field. The layout of the entire industry chain of the medical isotope.

- END -